Over half of patients diagnosed with bladder cancer have low-grade, noninvasive papillary bladder tumors that are unlikely to become life-threatening; however, patients are often treated with ...
UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
OSLO, Norway, March 24, 2025 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results